# US 2021/0330255 A1 · Neurological rehabilitation and training method utilizing oculomotor, visual and/or vestibular rehabilitation tasks on subjects with pharmacologically induced neuroplasticity > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0330255 A1 - Document ID: US20210330255A1 - Status: Published application - Kind: A1 - Application number: 17/316,077 - Filed: 2021-05-10 - Published: 2021-10-28 - Earliest claimed: 2018-11-08 - Assignees: Spryson Inc. - Applicants: Neurolign USA, LLC - Inventors: John Howison Schroeder; Robin C. Ashmore; Alexander D. Kiderman; Peter Charles Doyle - Web page: https://patentgrep.com/patent/US20210330255A1 ## CPC - A61B 5/4848: {Monitoring or testing the effects of treatment, e.g. of medication} - A61B 3/113: for determining or recording eye movement - A61B 5/11: Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb {(A61B5/1038 takes precedence; motion detection to correct for motion artifacts in physiological signals A61B5/721)} - A61B 5/4064: {Evaluating the brain (for intracranial pressure A61B5/031; for cerebral blood gases A61B5/14553; using EEG A61B5/369)} - A61K 31/13: Amines {(A61K31/04 takes precedence)} - A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)} - A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} - A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377) - A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2) - A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) - A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) - A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone - A61K 38/27: Growth hormone [GH], i.e. somatotropin - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients - G16H 20/70: relating to mental therapies, e.g. psychological therapy or autogenous training - A61B 2560/02: Operational features - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA ## Abstract A Neurological Rehabilitation method utilizing oculomotor, visual and/or vestibular rehabilitation tasks on subjects with pharmacologically induced neuroplasticity comprising the steps of Inducing neuroplasticity in a subject through administering of a neuroplasticity medicament; Providing a oculomotor, visual and vestibular rehabilitation task platform configured to supply visual targets to a subject for oculomotor, visual and vestibular rehabilitation tasks and track and record eye movement of the subject during oculomotor, visual and vestibular rehabilitation tasks; Performing oculomotor, visual and/or vestibular rehabilitation tasks on the platform with subjects during periods of pharmacologically induced neuroplasticity. The neuroplasticity medicament generally is comprising at least one of an antidepressant, a Brain Derived Neuro trophic factor enhancer, a steroid, a psychedelic, valproic acid, NDRI's, lithium carbonate, Metformin, N-Acetylcystine, and Human Growth Hormone. ## Claims ### Claim 1 A Neurological Rehabilitation or training method utilizing oculomotor, visual and/or vestibular rehabilitation tasks on subjects with pharmacologically induced neuroplasticity comprising the steps of A) Inducing neuroplasticity in a subject through administering of a neuroplasticity medicament; B) Providing a oculomotor, visual and vestibular rehabilitation task platform configured to supply visual and/or audible targets to a subject for oculomotor, visual and vestibular rehabilitation or training tasks and track and record eye movement of the subject during oculomotor, visual and vestibular rehabilitation tasks, and provide feedback to the clinician and/or the patient; C) Performing oculomotor, visual and/or vestibular rehabilitation or training tasks on the platform with subjects during periods of pharmacologically induced neuroplasticity. ### Claim 2 (depends on 1) The Neurological Rehabilitation method according to claim 1 wherein the neuroplasticity medicament is comprising at least one of an selective serotonin reuptake inhibitor, a Brain Derived Neuro trophic factor enhancer, a steroid, a psychedelic, valproic acid, NDRI's, lithium carbonate, Metformin, N-Acetylcystine, and Human Growth Hormone. ### Claim 3 (depends on 2) The Neurological Rehabilitation method according to claim 2 wherein the neuroplasticity medicament includes fluoxetine, sertraline, or other SSRI-categorized medication. ### Claim 4 (depends on 2) The Neurological Rehabilitation method according to claim 2 wherein the neuroplasticity medicament includes Brain Derived Neuro trophic factor enhancer including at least one of, ketamine and/or metabolic derivatives thereof, memantine, riluzole, and icariin. ### Claim 5 (depends on 2) The Neurological Rehabilitation method according to claim 2 wherein the neuroplasticity medicament includes steroids including at least one Neurosteroids. ### Claim 6 (depends on 5) The Neurological Rehabilitation method according to claim 5 wherein the neuroplasticity medicament includes at least one Neurosteroids comprising Pregnenolone, Dehydroepiandrosterone, Allopregnanolone, and their synthetic analogs. ### Claim 7 (depends on 2) The Neurological Rehabilitation method according to claim 2 wherein the neuroplasticity medicament includes steroids including at least one of testosterone, estrogen, and progesterone. ### Claim 8 (depends on 2) The Neurological Rehabilitation method according to claim 2 wherein the neuroplasticity medicament includes pharmacological psychedelics including at least one of tryptamines, amphetamines, and ergolines. ### Claim 9 (depends on 2) The Neurological Rehabilitation method according to claim 2 wherein the neuroplasticity medicament includes valproic acid. ### Claim 10 (depends on 2) The Neurological Rehabilitation method according to claim 2 wherein the neuroplasticity medicament includes NDRI. ### Claim 11 (depends on 2) The Neurological Rehabilitation method according to claim 2 wherein the neuroplasticity medicament includes metformin. ### Claim 12 (depends on 2) The Neurological Rehabilitation method according to claim 2 wherein the neuroplasticity medicament includes N-Acetylcystine. ### Claim 13 (depends on 2) The Neurological Rehabilitation method according to claim 2 wherein the neuroplasticity medicament includes Human growth hormone. ### Claim 14 (depends on 2) The Neurological Rehabilitation method according to claim 2 wherein the visual and/or vestibular rehabilitation or training tasks performed on the platform with subjects during periods of pharmacologically induced neuroplasticity are selected by the clinician. ### Claim 15 (depends on 2) The Neurological Rehabilitation method according to claim 2 further including the step of assessing the subject's performance of the visual and/or vestibular rehabilitation or training tasks performed on the platform during periods of the subject's pharmacologically induced neuroplasticity. ### Claim 16 (depends on 15) The Neurological Rehabilitation method according to claim 15 wherein the visual and/or vestibular rehabilitation or training tasks performed on the platform with subjects during periods of pharmacologically induced neuroplasticity and subsequent assessment are repeated. ### Claim 17 (depends on 16) The Neurological Rehabilitation method according to claim 16 wherein the visual and/or vestibular rehabilitation or training tasks performed on the platform with subjects during periods of pharmacologically induced neuroplasticity which are repeated are modified based upon the assessment of prior performances. ### Claim 18 (depends on 15) The Neurological Rehabilitation method according to claim 15 further including the step of providing feedback to the subject of the results of assessing the subject's performance of the visual and/or vestibular rehabilitation or training tasks performed on the platform during periods of the subject's pharmacologically induced neuroplasticity. ### Claim 19 (depends on 2) The Neurological Rehabilitation method according to claim 2 wherein the patient has a disorder including one of Traumatic Brain injury, mild or moderate, and concussion, Brain injury due to exposure to neurotoxins, Stroke, ischemia or hemorrhage, Alzheimer's, Parkinson's, Frontotemporal Dementias, Huntington's and Amyotrophic lateral sclerosis. ### Claim 20 (depends on 1) The Neurological Rehabilitation method according to claim 1 wherein the patient has a disorder including one of Traumatic Brain injury, mild or moderate, and concussion, Brain injury due to exposure to neurotoxins, Stroke, ischemia or hemorrhage, Alzheimer's, Parkinson's, Frontotemporal Dementias, Huntington's and Amyotrophic lateral sclerosis.